Nikolaos K. Robakis on Immunologic treatment of Alzheimer's disease.

COMMENT An interesting concept for trying new treatments for AD. 0 nikos.robakis

Paul Coleman on Vulnerability of small GABAergic neurons to human beta-amyloid pentapeptide.

COMMENT The abstract contains no discussion of loss of gabaergic neurons in AD. 0 Paul_Coleman

Richard Mayeux on Anti-inflammatory drugs protect against Alzheimer disease at low doses.

COMMENT This study provides evidence that the effect of nonsteroidals may be less than previously considered. 0 rpm2

Hiroshi Mori on ApoE genotype is a risk factor in nonpresenilin early-onset Alzheimer's disease families.

COMMENT The paper shows that ApoE does not clearly segregate with presenilin. 0 mori

Paul Coleman on Impaired phosphorylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimer type.

COMMENT The finding reported here is that IR for pCREB is decreased in AD hippocampus while total CREB level is unchanged. Other studies have shown altered expression of CREB in AD. 0 Paul_Coleman

Paul Coleman on Transgenic mice overexpressing the neurotrophic factor S-100 beta show neuronal cytoskeletal and behavioral signs of altered aging processes: implications for Alzheimer's disease and Down's syndrome.

COMMENT What is meant by "could be indicative of of the presence of neurofibrillary tangles?" 0 Paul_Coleman

Benjamin Wolozin on Presenilin-1 mutations in Alzheimer's disease.

COMMENT This is a striking finding indicating that mutations in PS1 affect more than the C-terminus of Ab. 0 bwolozin

Elliott Mufson on Risk of Alzheimer's disease among elderly patients with anemia: population-based investigations in Olmsted County, Minnesota.

COMMENT Interesting. 0 emufson

Paul Coleman on Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules.

COMMENT The concept of phosphorylation of multiple sites on tau giving greater inhibition of microtubule binding is useful. It would be interesting to have looked at the contribution of Ser 214. 0 Paul_Coleman

Paul Coleman on No hippocampal neuron or synaptic bouton loss in learning-impaired aged beta-amyloid precursor protein-null mice.

COMMENT This seems to be a well done study that has implications for the normal function of a beta. A question that seems to be left open is whether similar results would be obtained with a conditional null mouse. 0 Paul_Coleman

Benjamin Wolozin on Testosterone stimulates rapid secretory amyloid precursor protein release from rat hypothalamic cells via the activation of the mitogen-activated protein kinase pathway.

COMMENT Novel mechanism for regulating APP. 0 bwolozin

Edward Koo on Activity-dependent isolation of the presenilin- gamma -secretase complex reveals nicastrin and a gamma substrate.

COMMENT Given the recent papers on nicastrin knockout flies, this is the predicted result. Even before this paper, there is plenty of evidence to argue that the other ps interacting proteins, especially β-catenin, is not involved in the gamma activity. 0 edkoo

Nikolaos K. Robakis on Loss of somatostatin-like immunoreactivity in the frontal cortex of Alzheimer patients carrying the apolipoprotein epsilon 4 allele.

COMMENT If replicated, these data suggests that somatostatin may be used in AD treatment. 0 nikos.robakis

John Olney on The role of the amyloid protein precursor (APP) in Alzheimer's disease: does the normal function of APP explain the topography of neurodegeneration?

COMMENT Small presents a theoretical treatise aimed at explaining how the neuropathology of AD can be explained in terms of an amyloid disturbance. The hypothesis presented is rather weak and not supported by any hard data. 0 OlneyJ

Benjamin Wolozin on p35/cdk5 binds and phosphorylates beta-catenin and regulates beta-catenin/presenilin-1 interaction.

COMMENT The role of P35 in neurodegeneration appears to be increasingly important, and this article supports the importance of P35. 0 bwolozin